Donor-derived CAR-T therapy improves the survival of relapsed B-ALL after allogeneic transplantation compared with donor lymphocyte infusion
In this study, our data supported that donor-derived CAR-T therapy is a safe and potentially effective treatment for relapsed B-ALL after HSCT and may be superior to DLI.
Source: Human Cell - Category: Cytology Source Type: research
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Brain | Cancer & Oncology | Cytology | Hematology | Leukemia | Neurology | Stem Cell Therapy | Stem Cells | Study | Transplants